IHAM
RLAY icon

Integral Health Asset Management’s Relay Therapeutics RLAY Stock Holding History

Integral Health Asset Management’s Portfolio RLAY Stock Details RLAY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-750,000
Closed -$4.89M – 93
2024
Q2 		$4.89M Buy
750,000
+25,000
+3% +$171K 0.46% 53
2024
Q1 		$6.02M Buy
725,000
+125,000
+21% +$1.22M 0.56% 63
2023
Q4 		$6.61M Sell
600,000
-200,000
-25% -$1.69M 0.9% 51
2023
Q3 		$6.73M Buy
800,000
+100,000
+14% +$1.08M 0.93% 43
2023
Q2 		$8.79M Sell
700,000
-70,000
-9% -$871K 1.09% 39
2023
Q1 		$12.7M Buy
770,000
+145,000
+23% +$2.6M 2.55% 7
2022
Q4 		$9.34M Buy
625,000
+25,000
+4% +$479K 1.96% 22
2022
Q3 		$13.4M Buy
600,000
+163,738
+38% +$3.59M 2.61% 13
2022
Q2 		$7.31M Buy
436,262
+109,262
+33% +$2.34M 1.5% 24
2022
Q1 		$9.79M Buy
327,000
+102,000
+45% +$2.47M 2.55% 13
2021
Q4 		$6.91M Buy
225,000
+85,000
+61% +$2.69M 1.91% 19
2021
Q3 		$4.41M Buy
140,000
+20,000
+17% +$673K 1.27% 30
2021
Q2 		$4.39M Buy
120,000
+60,000
+100% +$1.98M 1.21% 34
2021
Q1 		$2.07M Buy
+60,000
New +$2.6M 0.59% 53

Other funds holding RLAY

SIAU
SB Investment Advisers (UK) London, United Kingdom $7.73B AUM 2.35% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
CC
Casdin Capital New York $1.32B AUM 76.62% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return
Norges Bank
Norges Bank Oslo, Norway $935B AUM
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
NI
Nextech Invest Zurich, Switzerland $1.42B AUM 304.47% 1-Year Est. Return

Integral Health Asset Management's RLAY Position: Q3 2024 in Review

Integral Health Asset Management sold out of Relay Therapeutics (RLAY) in Q3 2024, closing a stake of 750,000 shares — an estimated $4.89M sold.

Integral Health Asset Management first reported a position in RLAY in Q1 2021 and held it in 14 quarters. The position peaked at $13.4M in Q3 2022. 195 funds tracked by Wall St. Rank hold RLAY as of Q3 2024.

  • Integral Health Asset Management reported no remaining Relay Therapeutics position as of Q3 2024 after selling out during the quarter.
  • Integral Health Asset Management sold 750,000 Relay Therapeutics shares in Q3 2024, an estimated $4.89M.
  • Integral Health Asset Management first reported a position in Relay Therapeutics in Q1 2021 and held it in 14 quarters.
  • Integral Health Asset Management's Relay Therapeutics position peaked at $13.4M in Q3 2022.
  • 195 funds tracked by Wall St. Rank held Relay Therapeutics as of Q3 2024.

Based on Integral Health Asset Management's 13F filing for Q3 2024, filed 14 Nov 2024.